Access cutting-edge alopecia areata treatment through this phase 3 clinical trial at a research site in Iowa City. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Iowa City location
Preparing your pre-screening questions…
Access alopecia areata specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related alopecia areata treatment provided free
Check if you qualify for this alopecia areata clinical trial in Iowa City, IA
No-Cost Study Care
Local to Iowa City
Convenient for IA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate alopecia areata (AA). This study is seeking participants who are * 12 years or older (if permitted by the local IRB/EC and local regulatory health authority) * have AA with patchy hair loss. The current episode of hair loss has lasted for 6 months or longer but 10 years or less * do not have any other diseases or conditions affecting hair loss. Participants will have a 2 in 3 chance of receiving ritlecitinib 50 mg and a 1 in 3 chance of receiving placebo. The placebo looks like the study medicine but does not contain any active ingredients. Participants will not know what you have been assigned to receive. They will take ritlecitinib or placebo once daily by mouth at home for 24 weeks (6 months). After 24 weeks, the assigned treatment may stay the same or be changed to ritlecitinib 50 mg or 100 mg. This change will depend on how participants' alopecia areata responds to the treatment. Participants will receive the newly assigned treatment for another 23 weeks. About 4 weeks after the last dose, there will be a follow-up visit. At this visit, the team will check on your health. Participants will take part in this study for about 57 weeks. During this time, they will have study visits at the study clinic. Some study checks will be done by phone. We will compare the experiences of people receiving ritlecitinib to those of people who do not. This will help us determine if ritlecitinib is safe and effective.
Sponsor: Pfizer
Yes, this clinical trial (NCT07733765) has an active research site in Iowa City, IA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for alopecia areata treatment options in Iowa City, IA, this clinical trial (NCT07733765) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Iowa City research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced alopecia areata specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all alopecia areata clinical trials near you to find additional studies recruiting in your area.
See all pulmonary embolism clinical trials recruiting in Iowa City — not just this study.
Browse Pulmonary Embolism Trials in Iowa City →